TNFA (tnfpharma.com) Company Future Sales Volume

Public company logo of TNF Pharmaceuticals (TNFA)

TNF Pharmaceuticals possesses significant scientific weight in developing small-molecule treatments for fibrosis, while updated management has restructured R&D assets to target inflammation. The company's projected sales levels confirm these expectations, where the parameter mark equals 0.00. However, a lack of profitability and the risks of failed trials amid fierce competition create a threat of a decline in share value.

Company Revenue Forecast: TNF Pharmaceuticals (TNFA) for 07/25/2024 - 09/25/2025

Financial and market metric breakdowns for tnfpharma.com (TNFA)

- stock value and consensus price forecast:
Fundamental company valuation:TNF Pharmaceuticals
Product sample of TNF Pharmaceuticals

The development of oral TNF inhibitors and the success of the MYMD-1 drug determine the scaling potential of TNF Pharmaceuticals (TNFA). This sales revenue forecast correlates the current market value of TNF Pharmaceuticals (TNFA) with liquidity criteria and business volume. The price action reflects turnover instability prior to the release of official reports. The indicator's growth confirms the issuer's compliance with strict capitalization requirements, serving as the foundation for a long-term assessment of the assets' investment attractiveness.

Direct competitors

Projected Sales Volume HLN|KVUE (Kenvue Inc) - Company Future Revenue|Verona Pharma Corp - Company Future Sales Volume|Company Projected Revenue Volume MENS (Jyong Biotech Ltd)|ligand.com - Projected Sales Volume|amneal.com (AMRX) - Company Future Sales Volume|Perrigo (PRGO) - Company Projected Revenue|ALVO (Alvotech S.A.) - Company Projected Revenue|Company Future Sales Volume LQDA|Projected Sales Volume Galapagos Corp|Company Projected Revenue ANI Pharma (ANIP)|Projected Sales Volume MannKind Corporation (MNKD)|Company Projected Revenue Amphastar Pharmaceuticals Inc AMPH|Projected Sales Volume Pacira PCRX|ARS Pharmaceuticals Inc - Projected Sales Volume|TBPH - Projected Sales Volume|AQST (Aquestive Therapeutics) - Company Future Sales Volume|scPharmaceuticals, Inc. (SCPH) - Projected Sales Volume|Company Future Sales Volume TECX|Projected Sales Volume Tonix Pharma|Company Future Sales Volume SXTC (SXT Pharmaceuticals)|EPRX: Company Expected Revenue|BioHarvest Sciences - Company Future Sales Volume|EXOZ: Company Revenue Forecast|ORMP - Company Projected Revenue|ENTX: Company Projected Revenue|HYFT: Projected Sales Volume|Company Future Sales Volume ABVC BioPharma Inc|CPIX (Cumberland Corp) - Projected Sales Volume|Projected Sales Volume quantumbiopharma.com|Projected Sales Volume FGEN|Company Future Sales Volume Telomir Pharmaceuticals, Inc. TELO|Projected Sales Volume RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Company Expected Revenue|RLYB: Company Future Sales Volume|lexariabioscience.com (LEXX) - Company Future Sales Volume|Pulmatrix Inc (PULM) - Company Projected Revenue|PTHL: Company Projected Revenue Volume|APM (Aptorum Group Ltd) - Projected Sales Volume|Lyra Therapeutics Inc (LYRA) - Company Future Sales|Projected Sales Volume IBO|Projected Sales Volume cbdMD Corp (YCBD)|Projected Sales Volume PRFX (PainReform)|Company Future Sales Auris Medical (CYTO)|LIPO - Company Projected Revenue|Optinose (OPTN) - Company Future Sales Volume|Pieris (PIRS) - Company Projected Revenue|Company Expected Revenue PROC (Procaps Group S.A.)|Company Future Sales Volume PTPI|QLI: Company Future Revenue|Company Projected Revenue acelyrin.com (SLRN)|TFFP (TFF Pharma) - Company Future Revenue